Ifenprodil is under clinical development by Seyltx and currently in Phase II for Chronic Cough. According to GlobalData, Phase II drugs for Chronic Cough have a 16% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ifenprodil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ifenprodil overview
ifenprodil is under development for the treatment of idiopathic pulmonary fibrosis and chronic cough. The drug candidate is a repurposed drug administered through oral route and intravenous route. It acts by targeting NMDA 1 and NMDA-2B receptor. It was under development for the treatment of coronavirus disease 2019 (COVID-19), covid-19 associated pneumonia, acute respiratory distress syndrome and acute lung injury.
It was also under development for the treatment of small-cell lung cancer, acute lung injury, inflammatory bowel disease such as ulcerative colitis and Crohn's disease, pancreatic cancer, post-traumatic stress disorder and addiction.
Seyltx overview
Seyltx is involved in pharmaceuticals and healthcare, with a focus on therapy for chronic cough. The company is headquartered in Wellington, Delaware, the US.
For a complete picture of Ifenprodil’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
